ITOS

iTeos Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website iteostherapeutics.com
Employees(FY) 125
ISIN US46565G1040

Performance

-6.61%

-6.08%

-33.87%

-50.37%

-32.24%

YTD

-28.38%

Profile

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Advanced Technical Analysis

Technical Analysis of ITOS 2024-12-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 50 reflects a neutral stance. Overall, the combined Technical Score of 30 reinforces a bearish outlook, suggesting caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ITOS

Stock Rank

Recent News & Updates

2024-12-19 18:20
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo(Yahoo Finance)
2024-12-13 00:25
Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy(Yahoo Finance)
2024-12-11 19:55
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress(Globenewswire)
2024-11-25 18:00
iTeos to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-11 18:00
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-10-23 19:00
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress(Globenewswire)
2024-10-15 13:01
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc(Yahoo Finance)
2024-09-30 01:01
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc(Yahoo Finance)
2024-09-16 16:04
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths(Investor's Business Daily)
2024-09-16 06:26
Wedbush Raises Price Target on iTeos Therapeutics to $25 From $21, Keeps Outperform Rating(MT Newswires)
2024-09-15 21:12
ESMO 2024: TIGIT race tightens with first look at GSK/iTeosâ€™s TIGIT in NSCLC(Pharmaceutical Technology)
2024-09-14 08:10
TIGIT drug from iTeos shrinks lung tumors in trial(BioPharma Dive)
2024-09-14 02:30
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients(GlobeNewswire)
2024-09-13 14:30
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients(Globenewswire)
2024-08-28 16:30
iTeos to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-08-28 04:30
iTeos to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-25 09:14
We're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate(Simply Wall St.)
2024-08-20 08:30
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024(GlobeNewswire)
2024-08-19 20:30
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024(Globenewswire)
2024-08-13 08:42
Wells Fargo Initiates iTeos Therapeutics at Overweight With $31 Price Target(MT Newswires)
2024-08-08 08:20
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates(Zacks)
2024-08-08 07:00
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-08-07 19:00
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-08-05 13:43
ITeos Therapeutics Names David Feltquate Chief Medical Officer(MT Newswires)
2024-08-05 07:00
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer(GlobeNewswire)
2024-08-04 19:00
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer(Globenewswire)
2024-07-09 12:33
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial(Pharmaceutical Technology)
2024-07-08 07:54
iTeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment(MT Newswires)
2024-07-08 07:00
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK(GlobeNewswire)
2024-07-07 19:00
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK(Globenewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.